Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice
- 30 March 2010
- journal article
- Published by Wiley in Nephrology
- Vol. 15 (3) , 327-335
Abstract
To examine the additive protective effects of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone (Pio) and the angiotensin II receptor blocker candesartan (Cand) in a murine model of renal fibrosis: mice with unilateral ureteral obstruction (UUO). Mice were randomly assigned into four groups that after UUO received i.p. injections of either Pio (10 mg/kg/day), Cand (1 mg/kg/day), Cand + Pio or vehicle for 10 days. Physiological parameters, the degree of renal fibrosis and molecules related to renal fibrosis were analysed, and sham-operated mice were used as controls. Total collagen assay showed prominent renal fibrosis in the vehicle-treated mice, significantly attenuated renal fibrosis in the Cand-treated and the Pio-treated mice, and further attenuated renal fibrosis in the (Cand + Pio)-treated mice. Real-time reverse transcription polymerase chain reaction revealed that this attenuation pattern was also evident in the expression of the mRNA for transforming growth factor-beta, collagens I and III, and plasminogen activator inhibitor-1. Pioglitazone and candesartan have additive protective effects on renal fibrosis due to UUO in mice, suggesting that their use in combination would be an effective treatment for chronic kidney disease.Keywords
This publication has 28 references indexed in Scilit:
- Pioglitazone Enhances the Antihypertensive and Renoprotective Effects of Candesartan in Zucker Obese Rats Fed a High-Protein DietHypertension Research, 2008
- Beneficial Effects of Pioglitazone on Hypertensive Cardiovascular Injury Are Enhanced by Combination With CandesartanHypertension, 2008
- Effects of pioglitazone and candesartan on renal fibrosis and the intrarenal plasmin cascade in spontaneously hypercholesterolemic ratsAmerican Journal of Physiology-Renal Physiology, 2007
- Plasminogen Activator Inhibitor-1 in Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2006
- Optimizing ACE-Inhibitor Therapy for Chronic Kidney DiseaseNew England Journal of Medicine, 2006
- The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertensionAmerican Journal of Hypertension, 2005
- Chronic kidney disease: the global challengeThe Lancet, 2005
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- PAI-1 deficiency attenuates the fibrogenic response to ureteral obstructionKidney International, 2001
- Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trialThe Lancet, 1998